BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Drug Discovery

Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; hereafter referred to as “Dr. Reddy’s”), a g...

January 23, 2023 | News

ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production

Our valued customer Nouscom recently proclaimed that their sub-licensee, has initiated phase 1 clinical trials for VAC85135, a viral vector-based cancer va...

January 18, 2023 | News

Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC

World's first anti-PD-1 mAb for the first-line treatment of SCLC Making a new record with the median OS of 15.8 months in an international, mult...

January 18, 2023 | News

Pharma Industry Trend Brief: 2023 Manufacturing Trends

Worried about what the future holds for the pharmaceutical industry? This trend brief examines how manufacturers can take advantage of mo...

January 18, 2023 | News

Syneos Health Announces Partnership with Fosun Pharma USA to Launch Serplulimab

Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced a strategic partnership with Fos...

January 16, 2023 | News

Catalent and Ethicann Sign Development and License Agreement for New Fast-Dissolve Cannabinoid-Based Treatments

Under the terms of the license, financial details of which have not been disclosed, Catalent will look to develop Ethicann’s cannabidiol (CBD) an...

January 16, 2023 | News

Novotech Acquires US-based Drug Development Consulting Firm, CBR International

Novotech, the leading Asia Pacific centered biotech CRO today announced the acquisition of CBR International, a global product development, clinical oversi...

January 12, 2023 | News

Ajinomoto and Exelixis Enter Into a License Agreement to Discover and Develop Novel Antibody-Drug Conjugates for the Treatment of Cancer

Exelixis is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization o...

January 11, 2023 | News

ProPharma Group launches revolutionary new operating model to deliver life-saving drugs, medical devices and diagnostics to market faster

ProPharma Group – the end-to-end, global provider of regulatory, clinical and compliance services for the pharmaceutical, biotechnology and medical d...

January 10, 2023 | News

FDA approves LEQEMBI™ (lecanemab-irmb) under the Accelerated Approval pathway for the treatment of Alzheimer's disease

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that under the Accelerated Approval pathway the U.S. Food and Drug...

January 09, 2023 | News

Fosun Pharma and Henlius Entered into an Exclusive License Agreement for Serplulimab in the US

Fosun Pharma will have the right to commercialise serplulimab upon approval in the US, and Henlius will retain responsibility for development, manufacturin...

January 09, 2023 | News

Hummingbird Bioscience and Synaffix Enter License Agreement to Develop a Next Generation Antibody Drug Conjugate (ADC) Program

Synaffix B.V. (Synaffix), a biotechnology company focused on commercializing its clinical-stage platform technology for the development of antibody-drug co...

January 04, 2023 | News

Legend Biotech Announces Acceptance of Its New Drug Application for Ciltacabtagene Autoleucel (Cilta-Cel) in China

This submission is based on data from the confirmatory Phase 2 clinical study CARTIFAN-1 (NCT03758417) conducted in China, which evaluated the efficacy and...

January 03, 2023 | News

The Best of 2022: FDA Approvals and the Breakthroughs That Enabled Them

For a field like cancer research, in which progress can sometimes appear to happen slowly, it is especially important to remind ourselves of the crucial ad...

December 31, 2022 | News | By Calley Jones, PhD

Stay Connected